Page 21 - Morphosys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Today - Breaking & Trending Today

MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer's Disease Seite 1

14.11.2022 - GRADUATE studies did not meet primary endpointPLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 14, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the . Seite 1 ....

Jean Paul Kress , Ihre Einstellungen , Constellation Pharmaceuticals Inc , Chief Executive Officer , Clinical Trials , Constellation Pharmaceuticals , Kurserwartungen Des Analysten , Sie Kursziel , Emittent Alternativ ,

EQS-Adhoc: Ad hoc: MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer's Disease Seite 1

14.11.2022 - EQS-Ad-hoc: MorphoSys AG / Key word(s): Study results Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease 14-Nov-2022 / 07:12 CET/CEST Disclosure of an inside . Seite 1 ....

Program For Gantenerumab , Morphosy Licensing Partner Roche Provides Update , Early Alzheimer , Qs Adhoc ,

Pre-market Movers: Opiant Pharmaceuticals, MorphoSys, Tremor International, The Oncology Institute, Nektar Therapeutics

MARTINSRIED (dpa-AFX) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.50 A.M. ET).In the Green Opiant Pharmaceuticals, Inc. (OPNT) is up over 119% ....

Oncology Institute Inc , Orion Office , Tremor International Ltd , Opiant Pharmaceuticals Inc , Azure Power Global Limited , Silvergate Capital Corporation , Rallybio Corporation , Top Ships Inc , Oncology Institute , Trane Technologies , Nektar Therapeutics , Top Ships ,

MorphoSys AG: GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program ....

United States , Thomas Biegi , Julia Neugebauer , Eamonn Nolan , Morphosys Agview , Exchange Commission , American College Of Rheumatology , American College , Janus Kinase , Morphosy Annual Report ,

MorphoSys AG: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat Supporting Its Potential Application in a Broad Array of Advanced Tumors

The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR SymposiumPLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys ....

United States , Comunidad Autonoma De Cataluna , Thomas Biegi , Tim Demuth , Julia Neugebauer , Eamonn Nolan , Charles Drescher , Morphosys Agview , Gynecologic Cancer Research , Swedish Cancer Institute In Seattle , Development Officer , National Cancer Institute , European Organisation For Research , Exchange Commission , American Association For Cancer Research , Molecular Targets , Cancer Therapeutics , European Organisation , American Association , Cancer Research , Gynecologic Oncologist , Medical Director , Swedish Cancer Institute , Morphosys Chief Research , Morphosy Annual Report ,